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Orexin A and orexin B are hypothalamic neuropeptides initially identified as 
endogenous ligands for two orphan G-protein coupled receptors (GPCRs). A deficiency 
of orexin signaling results in the sleep disorder narcolepsy-cataplexy in humans, dogs, 
and rodents, a sleep disorder characterized by excessive daytime sleepiness and 
cataplexy. Multiple approaches, including molecular genetic, electrophysiological, 
pharmacological, and neuroanatomical studies have suggested that orexins play critical 
roles in the maintenance of wakefulness by regulating the function of monoaminergic 
and cholinergic neurons that are implicated in the regulation of wakefulness. Here, I 
review recent advances in the understanding of how orexins regulate sleep/wakefulness 
and prevent narcolepsy. 
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1. Discovery of orexin peptides 
Orexin A and orexin B were initially identified as endogenous ligands for two orphan 
G-protein coupled receptors (GPCR) (Sakurai et al., 1998): GPCRs for which 
endogenous ligands are unknown are referred to as “orphan” GPCRs. Molecular cloning 
studies showed that both orexin A and orexin B are derived from a common single 
precursor peptide, prepro-orexin. Since intracerebroventricular (ICV) injection of these 
peptides in rats acutely stimulated food consumption, they were named orexin A and 
orexin B after the Greek word “orexis,” meaning appetite. An mRNA encoding the same 
precursor peptide of hypocretin 1 (corresponding to orexin A) and hypocretin 2 (orexin 
B) was independently identified by de Lecea et al. as a hypothalamus-specific transcript 
(de Lecea et al., 1998). Orexin A and orexin B constitute a novel distinct peptide family. 
Orexin A is a 33-amino acid peptide with an N-terminal pyroglutamyl residue, two 
intrachain disulfide bonds, and C-terminal amidation, while orexin B is a 28-amino acid, 
C-terminally amidated linear peptide (Sakurai et al., 1998). The C-terminal half of 
orexin B is very similar to that of orexin A, whereas the N-terminal half is more 
variable. 
The actions of orexins are mediated by two receptors, named orexin 1 
(OX1R) and orexin 2 (OX2R) receptors (also known as HCRTR1 and HCRTR2) (de 
Lecea et al., 1998; Sakurai et al., 1998). OX1R shows a higher affinity for orexin A than 
orexin B by one-order, while OX2R binds orexin A and orexin B with similar affinities. 
Both receptors are Gq-coupled and caused strong excitatory effects on neurons 
examined thus far (Sakurai and Mieda, 2011), except in one study that reported the 
direct inhibitory action of orexin receptors on surprachiasmatic nucleus (SCN) neurons 
at night (Belle et al., 2014). 
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 Neurons expressing orexins (orexin neurons) are distributed within the 
perifornical lateral hypothalamus and send projections throughout the brain and spinal 
cord (Date et al., 1999; de Lecea et al., 1998; Nambu et al., 1999; Peyron et al., 1998; 
Sakurai et al., 1998; van den Pol, 1999). The number of these neurons has been 
estimated to be around 3,000 ~ 4,000 in rat and 70,000 in human brains (Kilduff and 
Peyron, 2000; Thannickal et al., 2000). Consistent with the broad projections of orexin 
neurons, Ox1r and Ox2r show partly overlapping but distinct distributions of their 
mRNA throughout the CNS (Lu et al., 2000; Marcus et al., 2001; Trivedi et al., 1998). 
 
2. Disruption of the orexin system causes narcolepsy 
Degenerative loss of orexin neurons in humans is associated with narcolepsy (type I 
narcolepsy: narcolepsy with cataplexy) (Nishino et al., 2000; Peyron et al., 2000; 
Thannickal et al., 2000), a debilitating neurological disorder, providing a unique 
perspective on the mechanisms of sleep/wakefulness control (Sakurai and Mieda, 2011; 
Zeitzer et al., 2006). A series of discoveries leading to this conclusion started with 
findings by two animal studies: (i) functionally null mutations in the Ox2r gene were 
found to be responsible for familial canine narcolepsy (Lin et al., 1999), and (ii) orexin 
knockout mice (orexin-/-) were shown to exhibit a phenotype strikingly similar to human 
narcolepsy (Chemelli et al., 1999). 
Human narcolepsy affects approximately 1 in 2,000 individuals in the United 
States (Mignot, 1998; Sakurai and Mieda, 2011; Zeitzer et al., 2006). The syndrome 
consists of excessive daytime sleepiness that often results in sleep attacks (sudden onset 
of non–rapid eye movement [NREM] sleep), cataplexy (sudden bilateral skeletal muscle 
weakening triggered by emotions, without consciousness impairment), hypnagogic 
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hallucinations, and sleep paralysis. These symptoms can be divided into two 
independent pathological phenomena (Dauvilliers et al., 2007). The first is 
dysregulation of NREM sleep onset: the inability to maintain a consolidated awake 
period, characterized by abrupt transitions from wakefulness to NREM sleep. This 
phenomenon manifests clinically as excessive daytime sleepiness or sleep attacks. The 
second pathological phenomenon is dysregulation of REM sleep onset: the pathological 
intrusion of REM sleep or REM atonia into wakefulness or at sleep onset. It is during 
these periods that patients may experience cataplexy, hypnagogic hallucinations, and 
sleep paralysis. 
Similarly, orexin–/– mice display a phenotype strikingly similar to human 
narcolepsy, with a markedly decreased duration of wakefulness episodes during the dark 
phase (i.e., inability to maintain a long wakeful period, or sleepiness), abrupt behavioral 
arrests with muscle atonia (i.e., potential cataplexy), which manifest as direct transitions 
from wakefulness to REM sleep in electroencephalogram/electromyogram (EEG/EMG) 
recordings, decreased REM sleep latency, and increased REM sleep time during the 
dark phase (Chemelli et al., 1999). Thus, orexins are likely to stabilize and maintain 
wakefulness episodes. 
Narcolepsy patients lose their orexin neurons likely due to autoimmune 
reaction, and mutations of prepro-orexin or orexin receptor genes are very rare in 
human narcolepsy (Crocker et al., 2005; Nishino et al., 2000; Peyron et al., 2000; 
Thannickal et al., 2000). In addition to orexins, orexin neurons contain other 
co-transmitters, such as glutamate, dynorphin, and neurotensin (Chou et al., 2001; 
Furutani et al., 2013; Rosin et al., 2003). Therefore, loss of these co-transmitters may 
also contribute to the symptoms of human narcolepsy. However, transgenic mice in 
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which orexin neurons are ablated postnatally by overexpression of a neurotoxic form of 
ataxin-3 (orexin-ataxin3 mice) showed essentially the same phenotype of sleep/wake 
regulation as orexin-/- mice, except for reduced amplitude of the circadian rhythm of 
REM sleep (Hara et al., 2001; Kantor et al., 2009). By contrast, mice with conditional 
and more complete ablation of orexin neurons demonstrated much more frequent 
cataplexy and less fragmented wakefulness than orexin-ataxin3 mice (Tabuchi et al., 
2014). Another study worth noting demonstrated that chronic overexpression of orexin 
peptides throughout the brain and ICV administration of orexin A prevented narcolepsy 
(Mieda et al., 2004). Collectively, although loss of orexin peptides is likely to contribute 
most of the symptoms of human narcolepsy, involvement of other factors expressed in 
orexin neurons cannot be excluded. 
 
3. Regulation of sleep/wakefulness by orexin neurons 
3.1 Neural Mechanism of Sleep/Wake Regulation 
Monoaminergic neurons, including locus coeruleus (LC) noradrenergic, dorsal and 
median raphe nuclei (DRN, MRN) serotonergic, and tuberomammillary nucleus (TMN) 
histaminergic neurons, project diffusely to the cerebral cortex, basal forebrain, thalamus, 
hypothalamus, and brainstem, and are thought to promote arousal (Sakurai and Mieda, 
2011; Saper et al., 2010). They are highly active during wakefulness, while they reduce 
their activities during NREM sleep and almost cease discharge during REM sleep 
(Aston-Jones and Bloom, 1981; McGinty and Harper, 1976; Steininger et al., 1999; 
Takahashi et al., 2010; Takahashi et al., 2006; Trulson and Jacobs, 1979). Other 
important wake-promoting signals are cholinergic fibers from the basal forebrain (BF) 
and the brainstem pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT). 
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PPT/LDT cholinergic neurons also interconnect with key forebrain targets. Their 
activity is highest during wakefulness and REM sleep. The BF neurons other than 
cholinergic ones are also implicated in sleep/wake regulation (Anaclet et al., 2015; Xu 
et al., 2015; Zant et al., 2016). Cholinergic, glutamatergic, and parvalbumin 
(PV)-expressing GABAergic neurons are wake/REM-active, are interconnected, and 
promote wakefulness (Xu et al., 2015). Cholinergic and PV GABAergic neurons also 
project to the cerebral cortex. 
In contrast to those neurons implicated in the promotion of wakefulness, 
GABA/galaninergic neurons in the ventrolateral preoptic area (VLPO) and median 
preoptic area (MnPO) are active during sleep, especially during NREM sleep, and are 
considered to be a sleep center (Saper et al., 2010). The chemogenetic activation of 
preoptic area indeed increased sleep (Saito et al., 2013; Zhang et al., 2015). 
Somatostatin (SOM)-expressing GABAergic neurons in the BF are also sleep-active, 
inhibit three other types of BF neurons, and promote sleep (Xu et al., 2015). Importantly, 
VLPO/MnPO neurons and monoaminergic neurons reciprocally inhibit each other. 
This section briefly summarized the regulatory network of sleep/wakefulness 
that has been demonstrated to interact with orexin neurons, as discussed in the next 
section. Excellent reviews on the known neural substrates of sleep/wakefulness 
regulation are available (e.g. Saper et al., 2010; Weber and Dan, 2016; as well as 
reviews in this special issue of Neurosci. Res., Miyazaki et al., 2017; Oishi and Lazarus, 
2017; Ono and Yamanaka, 2017). 
 
3.2 Orexin Neurons in Regulatory Circuit of Sleep/Wake 
Orexin neurons send their projections densely to nuclei involved in sleep/wakefulness 
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regulation, including the LC noradrenergic, raphe serotonergic, TMN histaminergic, 
PPT/LDT and BF cholinergic neurons (Chemelli et al., 1999; Horvath et al., 1999; 
Peyron et al., 1998; Yamanaka et al., 2002). In accordance with the innervation, neurons 
in these nuclei express OX1R and/or OX2R in different combinations (Marcus et al., 
2001; Mieda et al., 2011). ICV administration of orexin A in rodents reduces REM and 
NREM sleep, and increases wakefulness (Hagan et al., 1999; Mieda et al., 2011). 
Furthermore, optogenetic excitation of orexin neurons results in increases in the 
probability of an awakening event during both NREM and REM sleep (Adamantidis et 
al., 2007). The application of orexin A directly into the LC (Bourgin et al., 2000), TMN 
(Huang et al., 2001), BF (Espana et al., 2001; Thakkar et al., 2001), and LDT (Xi et al., 
2001) has also been reported to increase wakefulness. In vitro slice electrophysiology 
studies have shown that orexin A and orexin B increase firing rates of monoaminergic 
neurons in the LC (Horvath et al., 1999; van den Pol et al., 2002), DRN (Brown et al., 
2001; Liu et al., 2002), TMN (Bayer et al., 2001; Eriksson et al., 2001; Yamanaka et al., 
2002), and cholinergic neurons in the BF and LDT (Burlet et al., 2002; Eggermann et al., 
2001). These observations suggest that orexin neurons stabilize wakefulness by 
regulating these monoaminergic and cholinergic neurons. 
At the same time, orexin neurons receive projections from nuclei involved in 
sleep/wake regulation. GABAergic neurons in the preoptic area, including the VLPO, 
densely innervate orexin neurons (Sakurai et al., 2005; Yoshida et al., 2006). Orexin 
neurons are strongly inhibited by both the GABAA receptor agonist muscimol and the 
GABAB receptor agonist baclofen (Li et al., 2002; Xie et al., 2006; Yamanaka et al., 
2003a). Optogenetic stimulation of POA fibers indeed inhibits orexin neuronal activity 
(Saito et al., 2013). Orexin neurons are also innervated by BF cholinergic neurons (Li et 
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al., 2002; Sakurai et al., 2005; Xie et al., 2006). Carbacol, an agonist at muscarinic 
receptors, activates a subset of orexin neurons (Sakurai et al., 2005; Yamanaka et al., 
2003b). Thus, orexin neurons are inhibited by sleep-promoting neurons and activated by 
wake-promoting BF neurons: this regulation of orexin neurons is consistent with their 
proposed function to stabilize wakefulness. In contrast, wake-active serotonergic 
neurons in the MRN send inhibitory projections to orexin neurons (Li et al., 2002; 
Muraki et al., 2004; Sakurai et al., 2005). Noradrenergic neurons also have inhibitory 
effects on orexin neurons (Li et al., 2002; Yamanaka et al., 2006; Yamanaka et al., 
2003b). These negative feedback mechanisms may also be important for the fine 
adjustment of orexin neuronal activity to stabilize wakefulness (Tabuchi et al., 2013). 
Histamine has little effect on orexin neurons (Yamanaka et al., 2003b). Interestingly, a 
short two-hour period of total sleep deprivation was reported to change the action of 
noradrenaline on orexin neurons from excitation to inhibition in rats (Grivel et al., 2005). 
This mechanism may contribute to the growing sleepiness that accompanies sleep 
deprivation, although this phenomenon was not observed in mice (Yamanaka et al., 
2006). 
Local feedback circuits may also play important roles in the regulation of 
orexin neurons. Orexin neurons activate themselves directly and indirectly via local 
glutamatergic neurons, forming positive-feedback circuits that may stabilize the activity 
of the orexin neuron network (Li et al., 2002; Yamanaka et al., 2010). On the other hand, 
orexins also activate local GABAergic input to orexin neurons. Genetic disruption of 




3.3 Vigilance state-dependent firing of orexin neurons 
Considering symptoms of narcolepsy, orexin neurons are expected to be active during 
wakefulness and to be silent during sleep, as observed in wake-active monoaminergic 
neurons. Fos expression (an indicator of neuronal activity) in orexin neurons in rats is 
higher during the dark phase (active period) than during the light phase (rest period) 
(Estabrooke et al., 2001). Moreover, orexin level in CSF peaks during the dark period 
and decreases during the light period (Yoshida et al., 2001). In vivo single-unit 
recordings have confirmed such a wake-active firing pattern of orexin neurons (Lee et 
al., 2005; Mileykovskiy et al., 2005; Takahashi et al., 2008). Essentially, orexin neurons 
fired most actively during active waking, such as exploring, grooming, and eating, 
showed decreased discharge during quiet waking, were virtually silent during NREM 
sleep, and were almost silent but exhibited occasional firing during REM sleep. During 
the transition from sleep to wakefulness, orexin neurons fired prior to the onset of EEG 
activation, the EEG sign of wakefulness (Lee et al., 2005; Takahashi et al., 2008). In 
addition, they responded with a short latency to an arousing sound stimulus given 
during sleep, causing EEG activation (Mileykovskiy et al., 2005; Takahashi et al., 2008). 
These characteristics of orexin neurons clearly contrast with those of histaminergic 
neurons, which display waking-specific discharge, indicating that orexin neurons are 
not simply wake-active and are activated during emotional and sensorimotor conditions 
similar to those that trigger cataplexy in narcoleptic animals (Saper et al., 2010; 
Takahashi et al., 2005). This idea was further supported by the measurements of orexin 
release in the amygdala in narcoleptic human (Blouin et al., 2013). 
 Recent fiber photometry recordings revealed that orexin neurons are rapidly 
activated by stress, such as application of an air-puff to tail, exposure to novelty, and 
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immobility, as well as by nociception (Gonzalez et al., 2016; Inutsuka et al., 2016). 
These results are consistent with the fact that stress and nociception increase arousal. 
 
3.4 Causal relationship between the activity of orexin neurons and 
sleep/wakefulness 
Optogenetic and chemogenetic studies directly demonstrated the causal relationship 
between the activity of orexin neurons and sleep/wakefulness. Selective stimulation of 
these neurons via channelrhodopsin-2 (ChR2) increased the probability of transitions to 
wakefulness from either NREM or REM sleep (Adamantidis et al., 2007), while 
selective silencing of these neurons induced and increased NREM sleep in free-moving 
mice (Tsunematsu et al., 2011; Tsunematsu et al., 2013). Similarly, experiments using 
excitatory and inhibitory DREADDs (Designer Receptors Exclusively Activated by 
Designer Drugs) demonstrated that activation of orexinergic tone results in increased 
wakefulness time, while inhibition of these neurons results in reduced wakefulness 
(Sasaki et al., 2011). 
 
3.5 Synaptic input organization of orexin neurons 
Orexin neurons have been demonstrated to have unorthodox synaptic input organization 
(Horvath and Gao, 2005). They are controlled primarily by excitatory synaptic inputs, 
which outnumber inhibitory synapses by a ratio of 10:1. This organization is in sharp 
contrast to the fact that neuronal cell bodies in the central nervous system are either 
dominated by inhibitory inputs (long-projective neurons), or have an approximate ratio 
of excitatory to inhibitory inputs of 1:1. Such a unique input organization of orexin 
neurons may be a necessary element for the maintenance of a low threshold for arousal 
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and alertness. On the other hand, this circuitry may also be an underlying cause of 
insomnia. Furthermore, synaptic strength at glutamatergic synapses on neurons can be 
potentiated by prolonged wakefulness or fasting (Horvath and Gao, 2005; Rao et al., 
2007). These may suggest that synaptic potentiation in orexin neurons may be required 
to maintain prolonged wakefulness in animals and that the development of synaptic 
plasticity in orexin neurons may provide a mechanism through which the arousal 
threshold is regulated to determine the behavioral state of animals. 
 
3.6 Co-transmitters of orexin neurons 
In addition to orexins, orexin neurons contain other co-transmitters, such as glutamate, 
dynorphin, and neurotensin (Chou et al., 2001; Furutani et al., 2013; Rosin et al., 2003). 
Upon stimulation of orexin neurons, orexins caused sustained activation of TMN 
histaminergic neurons, while glutamate caused rapid, transient activation of these 
neurons. Therefore, orexins and glutamate are likely to translate distinct features of 
activity of orexin neurons into parallel, nonredundant control signals for downstream 
effectors (Schone et al., 2014; Schone et al., 2012). 
 Orexin and another co-transmitter, dynorphin, are packaged in the same 
synaptic vesicles within the hypothalamus. Nevertheless, orexin excites and dynorphin 
inhibits dopamine neurons of the ventral tegmental area. Orexin facilitates reward by 
attenuating the anti-reward effects of dynorphin, which is co-released with orexin 
(Muschamp et al., 2014). 
 As discussed in Section 2, narcoleptic phenotypes may be different between 
mice lacking orexins and mice lacking orexin neurons (Kantor et al., 2009; Tabuchi et 
al., 2014), which may suggest some roles of those co-transmitters of orexin neurons in 
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the symptoms of narcolepsy. 
 
4. Differential regulation of sleep/wakefulness by orexin receptors 
4.1 Spatial pattern of orexin receptor expression 
In clear contrast to the restricted localization of orexin mRNA expression exclusively in 
neurons distributed within the lateral hypothalamus (LH) and perifornical area (PFA) 
(de Lecea et al., 1998; Sakurai et al., 1998), Ox1r and Ox2r mRNA show wide 
distributions within the brain with partly overlapping but complementary distributions 
(Lu et al., 2000; Marcus et al., 2001; Mieda et al., 2011; Trivedi et al., 1998). This is 
consistent with the fact that orexin neurons project to almost all brain areas, with 
especially dense ones to monoaminergic and cholinergic nuclei of the brainstem and 
hypothalamus, which play important roles in the regulation of sleep/wakefulness states 
(Chemelli et al., 1999; Nambu et al., 1999; Peyron et al., 1998). These nuclei express 
OX1R and OX2R in differential manners (Marcus et al., 2001; Mieda et al., 2011). 
Histaminergic neurons in the TMN exclusively express Ox2r, while noradrenergic 
neurons in the LC exclusively express Ox1r. In the DRN and MRN, serotonergic 
neurons express Ox1r and/or Ox2r. In the LDT and PPT, cholinergic neurons express 
Ox1r but not Ox2r mRNA. Intriguingly, there are many GABAergic neurons expressing 
orexin receptors which are intermingled with these monoaminergic and cholinergic 
neurons (Mieda et al., 2011). 
 
4.2 Genetic dissection of sleep/wakefulness regulation by orexin receptors 
The fact that functionally null mutations in the Ox2r gene were responsible for two 
independent lines of familial narcoleptic canines indicates OX2R-mediated pathway as 
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a critical signaling in the regulation of sleep and wakefulness (Lin et al., 1999). Studies 
of orexin receptor-deficient mice (Ox1r -/- and Ox2r -/- mice) have provided a deeper 
insight into the differential roles of OX1R and OX2R (Sakurai, 2007). First, Ox1r 
-/-;Ox2r -/- mice demonstrate a narcoleptic phenotype nearly similar to that found in 
orexin-/- mice (Hondo et al., 2010; Sakurai, 2007), confirming that orexinergic 
regulation of sleep/wakefulness is mediated by these two receptors. Ox1r -/- mice show 
little abnormality in the states of sleep and wakefulness in the baseline condition 
(Hondo et al., 2010; Sakurai, 2007). In contrast, Ox2r -/- mice have clear narcoleptic 
symptoms, although their phenotype is milder as compared to that found in orexin-/- 
mice (Mochizuki et al., 2011; Sakurai, 2007; Willie et al., 2003). During the dark phase, 
Ox2r -/- mice did show abrupt cataplexy-like behavioral arrests, which correlated with 
the occurrence of direct transitions from wakefulness to REM sleep in EEG/EMG 
recordings. However, the frequency of such arrests was far less compared to orexin-/- 
mice (31-fold lower frequency in Ox2r -/- mice than in orexin-/- mice). Importantly, close 
observation of the behavior of Ox2r -/- mice during the dark phase using infrared 
videophotography uncovered a distinct variety of behavioral arrests with more gradual 
onsets (gradual arrests). Moreover, such gradual arrests turned out to also manifest in 
orexin-/- mice with a frequency similar to Ox2r -/- mice, in addition to plenty of abrupt 
arrests. Abrupt and gradual arrests have been characterized as the presumptive mouse 
correlates of cataplexy and sleep attacks in human narcolepsy, respectively, according to 
their behavioral, pharmacological, and electrophysiological features (Willie et al., 2003). 
Consistent with this observation, wakefulness episodes of Ox2r -/- mice are fragmented 
to an extent similar to those of orexin-/- mice, indicating that these two strains of mouse 
suffer from comparable sleepiness. In contrast, Ox2r -/- mice show normal REM sleep 
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latency and normal amounts of REM sleep, which are profoundly shortened and 
increased, respectively, in both orexin-/- mice and Ox1r -/-;Ox2r -/- mice (Sakurai, 2007; 
Willie et al., 2003). 
Collectively, mouse reverse genetic studies suggest that the normal regulation 
of wakefulness and NREM sleep transitions depends critically on OX2R activation, 
whereas the profound dysregulation of REM sleep control unique to narcolepsy emerges 
from a loss of signaling through both OX1R- and OX2R-dependent pathways. 
 The conclusion in the previous paragraphs has been further confirmed by a 
complementary experiment, i.e., comparing the arousal effects of ICV orexin A 
administration between wild-type, Ox1r -/-, and Ox2r -/- mice (Mieda et al., 2011). The 
effects of orexin A on wakefulness and NREM sleep were significantly attenuated in 
both Ox1r -/- and Ox2r -/- mice as compared to wild-type mice, with substantially larger 
attenuation in Ox2r -/- than in Ox1r -/- mice, suggesting the pivotal role of OX2R and the 
additional role of OX1R in the promotion of wakefulness. By contrast, the suppression 
of REM sleep via orexin A administration was marginally and similarly attenuated in 
both Ox1r -/- and Ox2r -/- mice, suggesting a comparable contribution of the two 
receptors to REM sleep suppression. The supplementary role of OX1R in the 
suppression of NREM sleep is consistent with the fact that Ox2r -/- mice with a 
C57BL/6J, but not C57BL/6J-129/SvEv-mixed, genetic background show less 
fragmented wakefulness than orexin-/- mice and Ox1r -/-;Ox2r -/- mice (Hasegawa et al., 
2014; Mochizuki et al., 2011; Sakurai, 2007; Willie et al., 2003), which suggests that 
OX1R is indispensable for the maintenance of wakefulness in the absence of OX2R. 
 
4.3 Comparison between the studies using mice and dogs 
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The conclusion drawn from mouse genetics apparently contradicts the fact that an 
inherited canine model of narcolepsy, which demonstrates a frequent occurrence of 
cataplexy as well as excessive sleepiness, is attributable solely to mutations of the Ox2r 
gene (Lin et al., 1999). Species differences (e.g., the precise expression patterns of the 
two orexin receptors) and/or selection bias may explain such an inconsistency. It should 
be noted that, even in canines, the absence of orexin peptides may cause severe 
narcoleptic symptoms as compared to Ox2r mutation. Early studies reported that 
narcoleptic Dobermans and Labradors with Ox2r mutations were much less severely 
affected with cataplexy than poodles with sporadic narcolepsy, which were supposed to 
lack orexin peptides (Baker et al., 1982). 
 
5. Neuronal pathways through which orexin neurons promote wakefulness and 
prevent narcolepsy 
5.1 TMN histaminergic neurons as a candidate downstream pathway of orexin 
neurons for the maintenance of wakefulness episodes 
The application of exogenous orexins has been shown to excite many types of neurons 
(Sakurai and Mieda, 2011) (also see above). As discussed earlier, monoaminergic and 
cholinergic nuclei of the hypothalamus and brainstem involved in the regulation of 
sleep and wakefulness especially receive dense projections of orexin neurons, express 
orexin receptors, and are activated by the application of orexin peptides in slice 
preparations. Furthermore, the administration of orexin A directly into monoaminergic 
and cholinergic nuclei has also been reported to increase wakefulness (Sakurai and 
Mieda, 2011). However, neurons activated by the pharmacological application of 
exogenous orexin may not necessarily be essential to the endogenous mechanisms by 
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which orexin neurons regulate sleep and wakefulness in a physiological condition. Thus, 
neurons directly downstream from orexin neurons in physiological conditions (i.e., the 
site and subtype of orexin receptors that mediate the wake-promoting and REM-gating 
effects by endogenous orexins) have remained incompletely understood. 
Histaminergic neurons in the TMN, which express OX2R exclusively, are 
good candidates for such downstream neurons contributing to the arousal effect of 
orexin. The wake-promoting effect of ICV orexin-A administration is both markedly 
attenuated by the histamine H1 receptor (H1R) antagonist pyrilamine (Yamanaka et al., 
2002) and is absent in H1r-/- mice (Huang et al., 2001). In addition, Mochizuki et al. 
produced OX2R-deficient mice by inserting a loxP-flanked transcription-disrupter (TD) 
gene cassette into the Ox2r gene, in which normal OX2R expression could be restored 
by Cre recombinase-mediated excision of TD cassette (Mochizuki et al., 2011). Using 
such an elegant genetic model, they showed that focal restoration of OX2R expression 
in the TMN and adjacent regions completely reversed the fragmentation of wakefulness 
episodes observed in their OX2R-deficient mice. 
However, this hypothesis remains controversial. Mice lacking both OX1R and 
H1R demonstrate no abnormality in sleep or wakefulness, which contradicts the idea 
that a H1R-mediated histaminergic pathway is the principal downstream component of 
OX2R-mediated orexinergic signaling (Hondo et al., 2010). Moreover, a recent study 
showed that increased probability of sleep-to-wakefulness transitions by optogenetic 
activation of orexin neurons does not depend on histamine (Carter et al., 2009). 
 
5.2 DRN serotonergic and LC noradrenergic neurons play differential roles in 
orexin neuron–dependent regulation of sleep/wakefulness 
 17 
Recently, Hasegawa and colleagues searched for monoaminergic and cholinergic nuclei 
of the brainstem and hypothalamus in which the focal restoration of orexin receptor 
expression by recombinant AAV vectors ameliorates narcoleptic phenotype of Ox1r 
-/-;Ox2r -/- mice (Hasegawa et al., 2014). If the regional restoration of orexin receptors in 
a certain brain region suppresses narcoleptic symptoms in these mice, that particular 
region can at least be regarded as one of the important downstream targets of orexin 
neurons. The targeted restoration of orexin receptor expression in the DRN and LC of 
these mice differentially inhibited cataplexy and the fragmentation of wakefulness (i.e., 
sleepiness), respectively. The suppression of cataplexy correlated with the number of 
serotonergic neurons restored with orexin receptor expression in the DRN, while the 
consolidation of fragmented wakefulness correlated with the number of noradrenergic 
neurons restored in the LC. Furthermore, the chemogenetic activation of these neurons 
using DREADD technology ameliorated narcolepsy in mice that lacked orexin neurons. 
These results suggest that DRN serotonergic and LC noradrenergic neurons play 
differential roles in the regulation of sleep and wakefulness by orexin neurons (Fig. 1). 
The suppression of cataplexy by DRN serotonergic neurons, but not by LC 
noradrenergic neurons, was an unexpected result (Hasegawa et al., 2014) because 
previous pharmacological and electrophysiological studies suggested that LC 
noradrenergic neurons are good candidates for downstream neurons to prevent cataplexy. 
For example, drugs that increase noradrenergic tone strongly suppress cataplexy in 
humans and canines, while blocking the noradrenergic signaling increases the frequency 
of cataplexy (Hirai and Nishino, 2011; Nishino and Mignot, 1997). In addition, LC 
neurons cease firing during cataplexy in canines (Wu et al., 1999). Nevertheless, the 
observations by Hasegawa and colleagues never deny the clinical importance of 
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enhancing noradrenergic systems for preventing cataplexy, yet simply indicate that the 
sole regulation of LC noradrenergic neurons by endogenous orexins is not sufficient to 
suppress cataplexy in narcoleptic mice. Non-LC noradrenergic neurons may also play 
an important role in the suppression of cataplexy by the pharmacological augmentation 
of systemic noradrenergic tone, which may be independent of the orexinergic 
regulation. 
The contribution of orexin signaling in DRN serotonergic neurons in the 
suppression of cataplexy fits with the observations that these neurons express both Ox1r 
and Ox2r (Mieda et al., 2011) and that the disruption of both OX1R- and 
OX2R-mediated pathways is required for the frequent occurrence of cataplexy, as 
described earlier (Fig. 1A) (Sakurai, 2007). DRN serotonergic neurons greatly reduce 
firing rates during cataplexy in canines (Wu et al., 2004). In addition, these neurons, as 
well as LC noradrenergic neurons, have been implicated in the suppression of REM 
sleep by inhibiting REM-on cholinergic neurons in the PPT/LDT and/or by activating 
REM-off GABAergic neurons in the ventrolateral periaqueductal gray (vlPAG) and 
adjacent lateral pontine tegmentum (LPT), also known as dorsal deep mesencephalic 
reticular nuclei (dDpMe) (Luppi et al., 2011). Indeed, DRN serotonergic neurons send 
dense projections to these brain areas, as well as to the amygdala (Hasegawa et al., 
2014), which suggests that DRN serotonergic neurons may coordinately control 
multiple brain regions involved in the regulation of REM sleep and emotion. 
As described above, the fragmentation of wakefulness is less severe in 
OX2R-/- mice than in orexin-/- mice and Ox1r -/-;Ox2r -/- mice with C57BL/6J genetic 
background (Mochizuki et al. 2011; Sakurai 2007), suggesting that OX1R plays an 
important role in the maintenance of wakefulness in the absence of OX2R (Mieda et al. 
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2011). Indeed, restoration of OX1R expression in the LC noradrenergic neurons of Ox1r 
-/-;Ox2r -/- mice stabilized wakefulness episodes to an extent comparable to those in 
Ox2r -/- mice (Hasegawa et al. 2014). Considering the fact that LC noradrenergic 
neurons exclusively express Ox1r in wild-type mice (Mieda et al. 2011), these neurons 
may be responsible for the contribution of OX1R to the maintenance of wakefulness, 
while another OX2R-mediated mechanism, most likely mediated by TMN histaminergic 
neurons, is further required for fully maintained wakefulness as in normal mice (Fig. 
1B). Recent optogenetic studies have provided support for the importance of the 
orexinergic regulation of LC noradrenergic neurons in the consolidation of wakefulness. 
For instance, there is a causal relationship between the firing of LC noradrenergic 
neurons and transitions from sleep to wakefulness (Carter et al. 2010). Moreover, the 
optogenetic inactivation of these neurons prevents the arousal effects of the optogenetic 
stimulation of orexin neurons (Carter et al. 2012). 
 
6. Pharmacological dissection of sleep/wakefulness regulation by orexin receptors  
A series of non-selective (dual) antagonists for orexin receptors (DORAs), as well as 
subtype-selective antagonists (SORAs), have been developed. On the one hand, these 
drugs are drawing people’s attention as novel medications for insomnia and other 
diseases (Mieda and Sakurai, 2013; Sakurai, 2014; Scammell and Winrow, 2011). On 
the other hand, they are also useful for studying the roles of each subtype in the 
regulation of sleep/wakefulness. 
To a large extent, results obtained by pharmacological studies utilizing 
DORAs and SORAs are consistent with those derived from genetic studies described in 
the previous sections (Table 1). Selective blockade of OX2R efficiently increases 
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NREM sleep and shortens NREM sleep latency (Betschart et al., 2013; Bonaventure et 
al., 2015a; Dugovic et al., 2009; Dugovic et al., 2014; Etori et al., 2014; Gotter et al., 
2016; Gozzi et al., 2011; Kuduk et al., 2015; Letavic et al., 2015). Blockade of both 
OX1R and OX2R does increase NREM sleep, but also causes a disproportionally large 
increase in REM sleep (Brisbare-Roch et al., 2007; Cox et al., 2010; Dugovic et al., 
2009; Dugovic et al., 2014; Etori et al., 2014; Hoyer et al., 2013; Winrow et al., 2012; 
Yoshida et al., 2015). Except one study showing increases in REM and NREM sleep 
with SB-334867 (Morairty et al., 2012), the selective blockade of OX1R alone does not 
cause any statistically significant effects on baseline sleep/wakefulness (Bonaventure et 
al., 2015b; Dugovic et al., 2009; Dugovic et al., 2014; Gozzi et al., 2011; Steiner et al., 
2013). However, OX1R blockade decreased NREM sleep latency after stress-induced 
arousal (Bonaventure et al., 2015b). Thus, OX2R is the principal regulator of 
wakefulness/NREM sleep transition, while both OX1R- and OX2R-mediated pathways 
are critical for gating REM sleep. Dugovic et al. further demonstrated that OX1R 
blockade counteracted the initiation and prolongation of the OX2R-SORA-induced 
NREM sleep possibly by increasing dopamine release (Dugovic et al., 2009; Dugovic et 
al., 2014). This result suggests that systemic inhibition of OX1R signaling by the 
administration of OX1R-SORA or by knocking out Ox1r gene alters activities in the 
brain regions that are different from the regulatory circuit of baseline sleep/wakefulness, 
including monoaminergic neurons, and secondarily reduce sleep. Such effects may 
mask a role of OX1R in the regulation of baseline sleep/wakefulness, which may 
explain the apparent discrepancy between the conclusion derived from pharmacological 
and knockout studies and that from the orexin receptor-restoration study (Hasegawa et 
al., 2014). 
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Administration of DORAs seldom induces cataplexy in normal animals, 
although there is a report that less than half of rats treated with high doses of 
SB-649868 demonstrated direct transitions from wakefulness to REM sleep (Dugovic et 
al., 2014). Therefore, as compared to the induction of NREM and REM sleep, nearly 
complete and/or chronic absence of both OX1R- and OX2R-mediated pathways may be 
needed for cataplexy to occur. This notion is consistent with the observation that the 
degeneration of more than 95% of orexin neurons is required for the occurrence of 
cataplexy in mice, whose frequency subsequently increases along with further 
degeneration (Tabuchi et al., 2014). 
 
7. Integration of external and internal environmental information by orexin 
neurons to regulate wakefulness 
In addition to sleep/wakefulness regulation, early descriptions of the projection patterns 
of orexin neurons had already suggested their involvement in a wide range of other 
physiological functions, such as feeding, autonomic regulation, and neuroendocrine 
regulation (Date et al., 1999; Peyron et al., 1998). Consistently, the central 
administration of orexin causes a wide variety of effects (Sakurai, 2007). Furthermore, 
systematical mappings of afferents to orexin neurons demonstrated that orexin neurons 
receive innervation from nuclei and regions involved in the regulation of feeding, 
autonomic and endocrine systems, reward, and emotion (Gonzalez et al., 2016; Sakurai 
et al., 2005; Yoshida et al., 2006). The activity of orexin neurons are also directly 
regulated by humoral factors that reflect the metabolic state of the body, including 
ghrelin, glucose, leptin, amino acids, and pH level (Burdakov et al., 2005; Karnani et al., 
2011; Williams et al., 2008; Williams et al., 2007; Yamanaka et al., 2003a). Therefore, 
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orexin neurons are well-placed to act as a hub that links information about the internal 
and external environments of an animal to vigilance levels and internal bodily functions 
that support various motivated behaviors (Sakurai, 2014). 
 Recent studies using genetically modified mice and orexin receptor 
antagonists has suggested that orexins are involved in the regulation of motivated 
behaviors, such as feeding, drinking, reward seeking, and emotional behavior. Orexins 
also regulate autonomic and endocrine systems, which accompany motivated behaviors. 
Orexinergic regulation of those behaviors was thoroughly reviewed previously (Mahler 
et al., 2014; Sakurai, 2014). Therefore, not only do orexin neurons contribute to 
sleep/wake regulation by stabilizing the activity of wake-promoting neural circuits, they 
are involved in sensing the body’s external and internal environments, and regulate 
states of sleep and wakefulness accordingly, which is beneficial for survival. They 
further coordinate autonomic tone and hormonal balance with arousal to maintain 
homeostasis or homeodynamics. The reciprocal interactions between orexin neurons 
and multiple neuronal systems raise the possibility that orexin neurons function as an 
interface between multiple regulatory systems including feeding, reward, emotional, 
circadian, autonomic, and endocrine systems. 
 For instance, when faced with a negative energy balance due to reduced food 
availability, mammals respond behaviorally with phases of increased wakefulness and 
alertness, which presumably enhances their ability to find food. However, orexin 
neuron-ablated mice are incapable of this fasting-induced arousal, indicating that orexin 
neurons are necessary for evoking adaptive behavioral arousal during fasting 
(Yamanaka et al., 2003a). The ability of orexin neurons to sense humoral metabolic cues, 
as well as innervations from regions that control metabolism and feeding, including the 
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hypothalamic arcuate nucleus, ventromedial hypothalamic nucleus, and nucleus of the 
solitary tract (NTS), are likely to enable orexin neurons to control arousal related to the 
peripheral energy balance (Mieda and Sakurai, 2009; Sakurai, 2007; Yamanaka et al., 
2003a). At the same time, orexin neurons also regulate the sympathetic nervous system 
and the hypothalamic-pituitary-adrenal (HPA) axis. Coordinated increases of 
sympathetic and HPA tone in response to fasting-induced arousal directed by orexin 
neurons may further help animals to execute adaptive behavior along with autonomic 
and neuroendocrine responses. 
 
8. Conclusions 
Symptoms of type I narcolepsy (narcolepsy with cataplexy) unequivocally reveal that 
orexins and orexin receptors play critical roles in the regulation of sleep/wake states. 
Orexin neurons are likely to stabilize wakefulness episodes by promoting wake-active 
monoaminergic neurons. In addition, the existence of reciprocal connections between 
the orexin system and multiple neuronal systems indicates that orexin neurons provide 
crucial links between multiple brain functions, such as energy homeostasis, the reward 
processing, emotion, and arousal. Future studies utilizing multiple approaches, such as 
molecular genetics, receptor subtype-selective pharmacology, optogenetics and 
chemogenetics, would lead to further understanding of the integrative physiology 
orchestrated by the orexin system. 
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FIGURE LEGENDS 
Figure 1. Proposed model for OX1R- and OX2R-mediated pathways in suppressing 
narcoleptic symptoms. (A) Prevention of cataplexy. Serotonergic neurons in the DRN 
mediate most of the anti-cataplectic effect of orexin neurons via both OX1R and OX2R, 
while other OX2R-mediated pathways may exist. (B) Consolidation of wakefulness 
episodes. LC noradrenergic neurons function as the OX1R-mediated pathway to 
stabilize wakefulness, while another OX2R-mediated pathway, possibly by TMN 
histaminergic neurons, is further required for the normal maintenance of wakefulness 
episodes. Modified from (Hasegawa et al., 2014) 
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NREM, time spent in NREM sleep after drug administration; REM/NREM, disproportionally large increase in REM sleep; DORA, non-selective orexin receptor 
antagonist; 1-SORA, selective OX1R antagonist; 2-SORA, selective OX2R antagonist; 1-SORA & 2-SORA, co-administration of 1-SORA and 2-SORA. In 
Bonaventire et al., (2015b), Compound 56 was administered in Ox2r-/- mice. aNREM sleep tended to increase in the first hour after administration; bScarce 
episodes of direct transitions from wakefulness to REM sleep were observed; cResults were different between species. 
Table 1. Summary of results obtained by pharmacological studies using DORAs and SORAs









Brisbare-Roch et al, 2007 Almorexant(ACT-078573)  Yes
Dugovic et al., 2009 Almorexant(ACT-078573)  Yes JNJ-10397049  No SB-408124  No
JNJ-10397049 &
SB-408124  No
Cox et al, 2010 Suvorexant(MK-4303)  Yes
Gozzi et al., 2011 JNJ-10307149  No GSK-1059865  No
Morairty et al., 2012 Almorexant(ACT-078573)  No EMPA  No SB-334867  No
Winrow et al, 2012 DORA22  Yes
Winrow et al, 2012 Filorexant (MK-6096)  Yes
Betschart et al., 2013 Suvorexant(MK-4303)  Yes IPSU  No
Steiner et al., 2013 ACT-335827  No
Dugovic et al., 2014 SB-649868b  Yes JNJ-10397049  No GSK-1059865  No JNJ-10397049 &GSK-1059865  Yes
Etori et al., 2014 Suvorexant(MK-4303)  Yes C1m  No
Bonaventure et al., 2015a JNJ-42847922  No
Bonaventure et al., 2015b Compound 56  No Ox2r
-/- &
Compound 56  Yes
Kuduk et al., 2015 MK-8133  No
Letavic et al., 2015 JNJ-42847922  No
Yoshida et al., 2015 E2006  Yes
Gotter et al., 2016 MK-1064  No/Yesc
